Cazitel Plus XL Tablets For Dogs

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

Praziquantel; Pyrantel embonate ; Febantel

から入手可能:

Chanelle Pharmaceuticals Manufacturing Limited

ATCコード:

QP52AA51

INN（国際名）:

Praziquantel; Pyrantel embonate ; Febantel

投薬量:

175,504,525 mg/tablet

医薬品形態:

Tablet

処方タイプ:

CAM: Companion Animal Medicine as defined in relevant national legislation

治療群:

Dogs

治療領域:

praziquantel, combinations

適応症:

Endoparasiticide

認証ステータス:

Authorised

承認日:

2012-03-02

製品の特徴

1
_ _1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Cazitel Plus XL Tablets For Dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCES:
Praziquantel
175 mg
Pyrantel Embonate
504 mg (equivalent to 175 mg pyrantel)
Febantel
525 mg
EXCIPIENTS:
QUALITATIVE COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS
Lactose monohydrate,
Microcrystalline cellulose,
Magnesium stearate,
Colloidal anhydrous silica,
Croscarmellose sodium,
Sodium laurilsulfate
Pork flavour
A yellow coloured oblong tablet with a breakline on both sides
The tablets can be divided into two equal parts.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Dogs.
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
In adult dogs: Treatment of mixed infections by nematodes and cestodes
of the following species
NEMATODES:
ASCARIDS:
_Toxocara canis_
,
_Toxascaris leonina_
(adult and late immature forms).
HOOKWORMS:
_Uncinaria stenocephala_
,
_Ancylostoma caninum_
(adults).
WHIPWORMS:
_Trichuris vulpis_
(adults).
CESTODES:
TAPEWORMS:
_Echinococcus_
species,
_(E. granulosus, E. multilocularis), Taenia_
species,
_(T. hydatigena, T. pisiformis, T. taeniformis), Dipylidium caninum_
(adult and immature forms).
3.3
CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
Do not use in cases of hypersensitivity to the active substances or to
any of the excipients.
3.4
SPECIAL WARNINGS
Fleas serve as intermediate hosts for one common type of tapeworm –
_Dipylidium caninum._
2
Tapeworm infestation is certain to reoccur unless control of
intermediate hosts such as fleas,
mice, etc. is undertaken.
Care should be taken to avoid the following practices because they
increase the risk of
development of resistance and could ultimately result in ineffective
therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended
period of time.
•
Underdosing, which may be due to underestimation of body weight,
misadministration of
the product.
3.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for safe use in the targe